BLUE BELL, Pa., March 4, 2014 /PRNewswire/ -- Inovio
Pharmaceuticals, Inc. (NYSE MKT: INO) ("Inovio" or the "Company"),
today closed its previously announced underwritten public offering
of 21,810,900 shares of the Company's common stock, including
2,844,900 shares of common stock issued pursuant to the
underwriter's exercise of its overallotment option, at the public
offering price of $2.90 per share.
The gross proceeds of this offering were approximately $63.3 million. Net proceeds to the Company, after
deducting the underwriter's discounts and commission and other
estimated offering expenses payable by the Company, were
approximately $59.2 million.
The Company intends to use the net proceeds received from the
sale of the common stock for general corporate purposes, including
clinical trial expenses, research and development expenses, general
and administrative expenses, manufacturing expenses and potential
acquisitions of companies and technologies that complement its
business.
Piper Jaffray & Co. and Stifel, Nicolaus & Company,
Incorporated acted as joint bookrunning managers for the offering.
Brean Capital and Maxim Group LLC acted as co-managers of the
offering.
The securities described above were offered by Inovio pursuant
to a shelf registration statement previously filed with and
declared effective by the Securities and Exchange Commission (the
"SEC") on February 13, 2014. A
prospectus supplement and the accompanying prospectus relating to
the securities offered has been filed with the SEC and is available
on the SEC's website at http://www.sec.gov. Copies of the
prospectus supplement and the accompanying prospectus relating to
the securities being offered may also be obtained from Piper
Jaffray & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis,
MN 55402, via telephone at 800-747-3924 or email at
prospectus@pjc.com; or from Stifel, Nicolaus & Company,
Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San
Francisco, CA 94104, via telephone at 415-364-2720 or email
at syndicateops@stifel.com.
This press release does not constitute an offer to sell or
the solicitation of offers to buy any securities of Inovio being
offered, and shall not constitute an offer, solicitation or sale of
any security in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Inovio Pharmaceuticals, Inc.
Inovio is engaged in the discovery and development of a new
generation of vaccines and immune therapies, called synthetic
vaccines, focused on cancers and infectious diseases. Inovio's
DNA-based SynCon® technology is designed to provide
universal protection against known as well as new unmatched strains
of pathogens such as influenza and also generate strong T-cell
responses to fight cancers and infectious diseases. Its preclinical
development and clinical programs include cervical dysplasia/cancer
(therapeutic), influenza (preventive), prostate cancer
(therapeutic), hepatitis C virus, hepatitis B virus, HIV, and
malaria vaccines. Inovio's partners and collaborators include
Roche, University of Pennsylvania,
Drexel University, National
Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in
Health/Malaria Vaccine Initiative, National Institute of Allergy
and Infectious Diseases, Merck, University of Southampton, United
States Military HIV Research Program, U.S. Army Medical Research
Institute of Infectious Diseases, HIV Vaccines Trial Network and
Department of Homeland Security.
This press release contains certain forward-looking
statements under the Private Securities Litigation Reform Act of
1995 relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, that pre-clinical studies and clinical trials may
not commence or be completed in the time periods anticipated, that
results from one study may not necessarily be reflected or
supported by the results of other similar studies and that results
from an animal study may not be indicative of results achievable in
human studies), the availability of funding to support continuing
research and studies in an effort to prove safety and efficacy of
electroporation technology as a delivery mechanism or develop
viable DNA vaccines, the adequacy of our capital resources, the
availability or potential availability of alternative therapies or
treatments for the conditions targeted by the company or its
collaborators, including alternatives that may be more efficacious
or cost-effective than any therapy or treatment that the company
and its collaborators hope to develop, evaluation of potential
opportunities, issues involving product liability, issues involving
patents and whether they or licenses to them will provide the
company with meaningful protection from others using the covered
technologies, whether such proprietary rights are enforceable or
defensible or infringe or allegedly infringe on rights of others or
can withstand claims of invalidity and whether the company can
finance or devote other significant resources that may be necessary
to prosecute, protect or defend them, the level of corporate
expenditures, assessments of the company's technology by potential
corporate or other partners or collaborators, our ability to secure
new partnerships and collaborations, capital market conditions, the
impact of government healthcare proposals and other factors set
forth in our Annual Report on Form 10-K for the year ended
December 31, 2012, our Form 10-Q for
the quarter ended September 30, 2013,
and other regulatory filings from time to time. There can be no
assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate. Although the Company may elect to do so at some
point in the future, the Company does not assume any obligation to
update any forward-looking statements and it disclaims any
intention or obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
CONTACTS:
|
|
|
|
Investors:
|
Bernie Hertel, Inovio
Pharmaceuticals, 858-410-3101, bhertel@inovio.com
|
Media:
|
Jeff Richardson,
Inovio Pharmaceuticals, 267-440-4211,
jrichardson@inovio.com
|
Photo -
http://photos.prnewswire.com/prnh/20131118/LA18202LOGO
SOURCE Inovio Pharmaceuticals, Inc.